

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- 1-97. (Canceled)
98. (Currently amended) A monoclonal antibody designated PA14 produced by ~~the~~ a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) or a fragment ~~thereof~~ of antibody PA14 which binds to an epitope of chemokine receptor 5 (CCR5) present on the surface of a cell expressing CCR5, which epitope comprises a combination of amino acid residues in (a) the N-terminus of CCR5, and (b) the second extracellular loop of CCR5.
99. (Previously presented) A hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) which produces a monoclonal antibody designated PA14.
100. (Currently amended) A monoclonal antibody or a fragment ~~thereof~~ of such antibody, wherein the antibody or the fragment ~~thereof~~ of such antibody binds to the same epitope as monoclonal antibody PA14 produced by the hybridoma cell line ~~designated PA14 (ATCC Accession No. HB-12610)~~ of claim 99.
101. (Currently amended) A monoclonal antibody or a fragment ~~thereof~~ of such antibody consisting of complementarity determining regions (CDRs) wherein said CDRs are derived

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 3

from a ~~hybridoma designated PA14 (ATCC Accession No. HB-12610)~~ the hybridoma cell line of claim 99.

102. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to ~~any of claims~~ claim 98, 100 or 101, wherein the antibody or fragment ~~thereof~~ of such antibody is a humanized antibody.

103. (Previously presented) The monoclonal antibody according to claim 102, wherein the antibody comprises a framework from a human immunoglobulin molecule.

104. (Previously presented) The monoclonal antibody according to claim 103, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.

105-116. (Canceled)

117. (Canceled).

118. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 101, wherein the antibody is a humanized antibody.

119. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 117, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.

120. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 117, wherein

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 4

the antibody comprises a framework from a human IgG4 immunoglobulin molecule.

121. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim ~~118~~ 102, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.

122. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim ~~118~~ 102, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.

123. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 100, wherein the antibody is a chimeric antibody.

124. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 101, wherein the antibody is a chimeric antibody.

125. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 123, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.

126. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 123, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.

127. (Currently amended) The monoclonal antibody or fragment

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 5

~~thereof~~ of such antibody according to claim 124, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.

128. (Currently amended) The monoclonal antibody or fragment ~~thereof~~ of such antibody according to claim 124, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.

129. (Currently amended) The monoclonal antibody ~~or~~ fragment ~~thereof~~ according to claim 100, wherein the antibody fragment is a monovalent fragment of an antibody.

130. (Currently amended) The monoclonal antibody ~~or~~ fragment ~~thereof~~ according to claim 101, wherein the antibody fragment is a monovalent fragment of an antibody.

131. (Currently amended) The monovalent antibody ~~or~~ fragment ~~thereof~~ according to claim 129, wherein the antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.

132. (Currently amended) The monovalent antibody ~~or~~ fragment ~~thereof~~ according to claim 129, wherein the antibody fragment comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.

133. (Currently amended) The monovalent antibody ~~or~~ fragment ~~thereof~~ according to claim 130, wherein the antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 6

134. (Currently amended) The monovalent antibody ~~or~~ fragment ~~thereof~~ according to claim 130, wherein the antibody fragment comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.